Clinical Trials
50 trialsNCT05519085 2026-05-27
SUCCESSOR-1
Celgene
Phase 3 Recruiting
NCT06158841 2026-05-27
CERVINO
AbbVie
Phase 3 Recruiting
NCT07555938 2026-05-27
CEVOLUTION
Hoffmann-La Roche
Phase 3 Recruiting
NCT07227311 2026-05-26
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
Phase 2 Recruiting
NCT01946477 2026-05-22
POM MM 014
Celgene
Phase 2 Completed
NCT06152575 2026-05-22
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT07138209 2026-05-22
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT04302324 2026-05-20
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT04902443 2026-05-20
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT05911321 2026-05-20
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT01053949 2026-05-14
IFM2009-02
University Hospital, Lille
Phase 2 Completed
NCT06615479 2026-05-13
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT06948084 2026-05-13
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT07463807 2026-05-13
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
NCT07579234 2026-05-12
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD
Phase 3 Recruiting
NCT04181827 2026-05-11
CARTITUDE-4
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04973605 2026-05-11
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
BeOne Medicines
Phase 1/2 Recruiting
NCT05669989 2026-05-11
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Sanofi
Phase 2 Active not recruiting
NCT04108195 2026-05-08
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04722146 2026-05-08
MajesTEC-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05050097 2026-05-08
MonumenTAL-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05083169 2026-05-08
MajesTEC-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05438043 2026-05-08
A Study of Daratumumab
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06768489 2026-05-08
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07569757 2026-05-08
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT06413498 2026-05-07
iMMagine-3
Gilead Sciences
Phase 3 Recruiting
NCT04126200 2026-05-06
DREAMM 5
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT06106945 2026-05-06
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
AstraZeneca
Phase 1/2 Recruiting
NCT05020236 2026-05-05
MAGNETISMM-5
Pfizer
Phase 3 Recruiting
NCT02343042 2026-05-04
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Active not recruiting
NCT04508790 2026-05-04
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
City of Hope Medical Center
Phase 2 Recruiting
NCT07560449 2026-05-01
QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms
Qilu Pharmaceutical Co., Ltd.
Phase 2 Not yet recruiting
NCT02659930 2026-04-30
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT07391657 2026-04-30
DURGA-4
AstraZeneca
Phase 3 Recruiting
NCT05389423 2026-04-28
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07532525 2026-04-16
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
University of Michigan Rogel Cancer Center
Phase 1 Not yet recruiting
NCT02719613 2026-04-15
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Bristol-Myers Squibb
Phase 2 Completed
NCT07523737 2026-04-15
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Beijing Tongren Hospital
Phase 2 Recruiting
NCT04667663 2026-04-13
CPD-DARA
Cancer Trials Ireland
Phase 1 Active not recruiting
NCT05455320 2026-04-13
MonumenTAL-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05572515 2026-04-13
MajesTEC-9
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03984097 2026-04-09
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
Phase 1 Completed
NCT04162210 2026-03-31
DREAMM-3
GlaxoSmithKline
Phase 3 Active not recruiting
NCT04835129 2026-03-27
IMPEDE
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT07452198 2026-03-25
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT04910568 2026-03-19
CAMMA 1
Genentech, Inc.
Phase 1 Active not recruiting
NCT04883242 2026-03-13
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
University of Washington
Phase 2 Active not recruiting
NCT06208150 2026-03-13
MonumenTAL-6
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05730036 2026-03-06
LINKER-MM3
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT04094961 2026-03-05
Ixazomib + Pomalidomide + Dexamethasone In MM
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting